Your browser doesn't support javascript.
loading
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson, Jeremy S; Palomba, M Lia; Gordon, Leo I; Lunning, Matthew A; Wang, Michael; Arnason, Jon; Mehta, Amitkumar; Purev, Enkhtsetseg; Maloney, David G; Andreadis, Charalambos; Sehgal, Alison; Solomon, Scott R; Ghosh, Nilanjan; Albertson, Tina M; Garcia, Jacob; Kostic, Ana; Mallaney, Mary; Ogasawara, Ken; Newhall, Kathryn; Kim, Yeonhee; Li, Daniel; Siddiqi, Tanya.
Afiliação
  • Abramson JS; Massachusetts General Hospital Cancer Center, Boston, MA, USA. Electronic address: jabramson@mgh.harvard.edu.
  • Palomba ML; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gordon LI; Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA.
  • Lunning MA; University of Nebraska Medical Center, Omaha, NE, USA.
  • Wang M; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Arnason J; Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Mehta A; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Purev E; University of Colorado School of Medicine, Aurora, CO, USA.
  • Maloney DG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Andreadis C; University of California, San Francisco, San Francisco, CA, USA.
  • Sehgal A; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
  • Solomon SR; Northside Hospital Cancer Institute, Atlanta, GA, USA.
  • Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Albertson TM; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Garcia J; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Kostic A; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Mallaney M; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Ogasawara K; Bristol-Myers Squibb, Princeton, NJ, USA.
  • Newhall K; Bristol-Myers Squibb, Seattle, WA, USA.
  • Kim Y; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Li D; Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA, USA.
  • Siddiqi T; City of Hope National Medical Center, Duarte, CA, USA.
Lancet ; 396(10254): 839-852, 2020 09 19.
Article em En | MEDLINE | ID: mdl-32888407
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Linfoma Difuso de Grandes Células B / Antígenos CD19 Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia Adotiva / Linfoma Difuso de Grandes Células B / Antígenos CD19 Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article